María Alejandra Carrasco1. 1. Centrovision Mendoza, National University of Cuyo, Mendoza, Argentina. macarras73@gmail.com
Abstract
PURPOSE: To report an 81-year-old woman with corneal neovascularization secondary to herpetic stromal keratitis treated with subconjunctival bevacizumab and to discuss the role of this novel antiangiogenic treatment. METHODS: Case report and review of medical literature. RESULTS: A dramatic regression of corneal vessels was observed 1 week after the injection. After a 3-month follow-up, there was no recurrence of corneal revascularization. CONCLUSIONS: Bevacizumab may be a valid complementary treatment in patients with corneal neovascularization caused by herpetic stromal keratitis.
PURPOSE: To report an 81-year-old woman with corneal neovascularization secondary to herpetic stromal keratitis treated with subconjunctival bevacizumab and to discuss the role of this novel antiangiogenic treatment. METHODS: Case report and review of medical literature. RESULTS: A dramatic regression of corneal vessels was observed 1 week after the injection. After a 3-month follow-up, there was no recurrence of corneal revascularization. CONCLUSIONS:Bevacizumab may be a valid complementary treatment in patients with corneal neovascularization caused by herpetic stromal keratitis.
Authors: Alejandro Lichtinger; Sonia N Yeung; Peter Kim; Maoz D Amiran; Uri Elbaz; Allan R Slomovic Journal: Int Ophthalmol Date: 2013-05-31 Impact factor: 2.031